Opthea Secures $170 Million Financing and $90 Million Private Placement

Singapore – August 23, 2022 – Cooley advised Opthea, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, on its non-dilutive financing arrangement for up to $170 million with Launch Therapeutics (Launch Tx), a recently formed development company backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth. The firm also advised on Opthea’s concurrent $90 million private institutional placement and share purchase plan. Lawyers Milson Yu, Ellie Guadiana, Tim Pitrelli, Mischi a Marca and Ferish Patel led the Cooley team advising Opthea.

Cooley previously advised Opthea on its $128 million initial public offering, which at the time marked the largest IPO conducted by a development-stage Australian life sciences company and the largest Australian biotech capital raise in a secondary Nasdaq IPO.

Headquartered in Melbourne, Australia, Opthea is developing novel therapies to address an unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Opthea’s lead product candidate, OPT-302, is in pivotal phase 3 clinical trials, and to achieve broader inhibition of the vascular endothelial growth factor (VEGF) family, it is being developed for use in combination with anti-VEGF-A monotherapies, with the goal of improving overall efficacy and demonstrating superior vision gains over those achieved by inhibiting VEGF-A alone. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe, and a total workforce of 3,300.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.